Fresenius Kabi Deutschland Gmbh

Merck Patent Gesellschaft MIT Beschrankter Haftung

Sanofi-a Ventis Deutschland Gmbh

Jurgen Hemberger

Michele Orlando

Klaus Sommermeyer

Wolfram Eichner

Sven Frie

Katharina Lutterbeck

Cornelius Jungheinrich

Roland Scharpf

Olaf Zeckai

Guido Melzer

Richard R Schmidt

Jan-Peter Spengler

Jasmin Groeschke

Matthias Scharf

Michael Schrack

Hanno Juhnke

Egbert Muller

Michael Morr

Willy Kinzy

Michael Fischer

Jeanne Delbos-Krampe

Karl-Heinz Jung

Barbara Spahngehl

Anne Boker

The present invention relates to a method of testing the mechanical integrity of a cartridge () containing a medicament and being arranged inside a drug delivery device (). The invention also relates to a testing arrangement and to a respective drug delivery device, wherein the method comprises the steps of: acoustically stimulating the cartridge (), measuring of the cartridge's () acoustic response () to the acoustic stimulation (), comparing the acoustic response () with a standard response () of an intact cartridge (), and determining the mechanical integrity of the cartridge () on the basis of the comparison.

Method and arrangement for acoustically testing the mechanical integrity of a cartridge

The invention relates to a method for coupling proteins to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the protein is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the protein which reacts with the aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of conjugates and compositions for the prophylaxis or therapy of the human or animal body.

Coupling proteins to a modified polysaccharide

The invention relates to a method for coupling low-molecular weight substances to a starch-derived modified polysaccharide. The binding interaction between the modified polysaccharide and the low-molecular weight substance is based on a covalent bond which is the result of a coupling reaction between the terminal aldehyde group or a functional group of the modified polysaccharide molecule resulting from the chemical reaction of this aldehyde group and a functional group of the low-molecular weight substance which reacts with this aldehyde group or with the resulting functional group of the polysaccharide molecule. The bond directly resulting from the coupling reaction can be optionally modified by a further reaction to the aforementioned covalent bond. The invention further relates to pharmaceutical compositions that comprise conjugates formed in this coupling process and to the use of said conjugates and compositions for the prophylaxis or therapy of the human or animal body.

Coupling low-molecular substances to a modified polysaccharide

The invention relates to compounds, comprising a conjugate of hydroxyalkyl starch (HAS) and an active agent, whereby the hydroxyalkyl starch is either directly covalently bonded to the active agent, or by means of a linker. The invention further relates to methods for the production of a covalent HAS-active agent conjugate, whereby HAS and an active agent are reacted in a reaction medium, characterised in that the reaction medium is water or a mixture of water and an organic solvent, comprising at least 10 wt. % water.

Conjugates of hydroxyalkyl starch and an active agent

The present invention relates to pharmaceutically active oligosaccharide conjugates having the formula: (X&#x2014;Y)&#x2014;S, wherein component X is a pharmaceutically active compound, Y is a bifunctional linker, and S is an oligosaccharide consisting of 1 to 20 saccharide units, n is equal or less than the number of the saccharide units in the oligosaccharide S, and m is, independent of n, 0 or 1. In addition, the present invention is directed to a process of preparing compounds of the present invention, comprising the step of coupling components X and S directly or indirectly by means of a bifunctional linker group. Furthermore, the present invention relates to the use of said pharmaceutically active oligosaccharide conjugates as a medicament as well as to pharmaceutical compositions, freeze-dried pharmaceutical compositions, and a kit, all of which comprise at least one of said pharmaceutically active oligosaccharide conjugates.

Pharmaceutically active oligosaccharide conjugates

Inhibitor of collagen-stimulated platelet aggregation

Nucleotide-containing sorbent for affinity chromatography

The invention relates to a process for the stereoselective preparation of .beta.-L-fucopyranosyl phosphates via the trichloroacetimidates of protected L-fucose and the synthesis and purification of very pure GDP-fucose from the .beta.-L-fucopyranosyl phosphates.

Process for the stereoselective preparation of .beta.-fucopyranosyl

Growing community of inventors

Aschaffenburg, Germany

Jurgen Hemberger